H1B Report
Side-by-side comparison

AMNEAL PHARMACEUTICALS LLC vs Microsoft Corporation

A direct H-1B sponsorship comparison built from the same DOL Labor Condition Application data that drives every page on H1B Report. Total filings, outcome rates, top occupations and yearly demand side-by-side.

Entity A
AMNEAL PHARMACEUTICALS LLC
NJRank #FEIN 90-0186021
Entity B
Microsoft Corporation
WARank #5FEIN 91-1144442

Key metrics

All percentages are share of total LCAs filed by each sponsor.

MetricAMNEAL PHARMACEUTICALS LLCMicrosoft Corporation
Total filings45372,912
Certified %94.04%94.30%
Denied %0.66%0.15%
Withdrawn %2.65%0.69%
Cert-withdrawn %2.65%4.85%
Rank#5
Active yearsFY2010–FY2026FY2010–FY2026
Worksite stateNJWA

Outcomes — AMNEAL PHARMACEUTICALS LLC

DOL case-status mix.

Outcome breakdown: Certified 94.0%, Cert-withdrawn 2.6%, Withdrawn 2.6%, Denied 0.7%
Outcome breakdown
OutcomeShare
Certified94.0%
Cert-withdrawn2.6%
Withdrawn2.6%
Denied0.7%
Certified94.0%
Cert-withdrawn2.6%
Withdrawn2.6%
Denied0.7%

Outcomes — Microsoft Corporation

DOL case-status mix.

Outcome breakdown: Certified 94.3%, Cert-withdrawn 4.9%, Withdrawn 0.7%, Denied 0.2%
Outcome breakdown
OutcomeShare
Certified94.3%
Cert-withdrawn4.9%
Withdrawn0.7%
Denied0.2%
Certified94.3%
Cert-withdrawn4.9%
Withdrawn0.7%
Denied0.2%

Yearly filing volume

Year-over-year H-1B demand for each sponsor.

AMNEAL PHARMACEUTICALS LLC
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY201013
FY201125
FY201225
FY201324
FY201439
FY201551
FY201638
FY201740
FY201838
FY201945
FY20202
FY20216
FY20223
FY202314
FY202434
FY202525
FY202631
Microsoft Corporation
Time series: 17 points from FY2010 to FY2026
Time series
PeriodValue
FY20104,407
FY20114,184
FY20124,005
FY20133,832
FY20143,674
FY20154,476
FY20164,919
FY20174,884
FY20185,457
FY20196,000
FY202051
FY2021110
FY2022150
FY20232,791
FY20249,492
FY20259,362
FY20265,118

Top 5 occupations — AMNEAL PHARMACEUTICALS LLC

Top 5 occupations — Microsoft Corporation

Swap an entity
Replace either sponsor above without losing the comparison. 2-way for now; 3+ comparison coming soon.